CN110121343B - 用作gpr120调节剂的双环化合物 - Google Patents
用作gpr120调节剂的双环化合物 Download PDFInfo
- Publication number
- CN110121343B CN110121343B CN201780068712.9A CN201780068712A CN110121343B CN 110121343 B CN110121343 B CN 110121343B CN 201780068712 A CN201780068712 A CN 201780068712A CN 110121343 B CN110121343 B CN 110121343B
- Authority
- CN
- China
- Prior art keywords
- compound
- mmol
- preparation
- mammals
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393619P | 2016-09-12 | 2016-09-12 | |
| US62/393,619 | 2016-09-12 | ||
| PCT/US2017/050964 WO2018049328A1 (en) | 2016-09-12 | 2017-09-11 | Bicyclic compounds useful as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110121343A CN110121343A (zh) | 2019-08-13 |
| CN110121343B true CN110121343B (zh) | 2023-11-03 |
Family
ID=61562078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780068712.9A Active CN110121343B (zh) | 2016-09-12 | 2017-09-11 | 用作gpr120调节剂的双环化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10865201B2 (enExample) |
| EP (1) | EP3509588B1 (enExample) |
| JP (1) | JP7065081B2 (enExample) |
| KR (1) | KR102539877B1 (enExample) |
| CN (1) | CN110121343B (enExample) |
| CA (1) | CA3041038A1 (enExample) |
| WO (1) | WO2018049328A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7086942B2 (ja) | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| CA3041038A1 (en) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| AU2019255363A1 (en) * | 2018-04-20 | 2020-11-05 | Krish Biotech Research Private Limited | Method of treatment of non-alcoholic steatohepatitis, nash |
| CN111499592B (zh) * | 2020-03-14 | 2023-06-23 | 江苏省农用激素工程技术研究中心有限公司 | 5-氨甲基糖精的合成方法 |
| CN111574414A (zh) * | 2020-05-20 | 2020-08-25 | 上海毕得医药科技有限公司 | 一种4-溴-2-甲氧基苯磺酰氯的合成方法 |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| CN114685395A (zh) * | 2020-12-29 | 2022-07-01 | 浙江大学 | 一种2,3-二氢苯并[d]异噻唑类化合物及其应用 |
| WO2024046323A1 (zh) * | 2022-08-29 | 2024-03-07 | 山东大学 | 一种苯并五元氮环类化合物、其制备方法及医药用途 |
| CN116730945B (zh) * | 2023-08-10 | 2023-11-17 | 北京惠宇乐邦环保科技有限公司 | 糖精的制备方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0548934A1 (en) * | 1991-12-25 | 1993-06-30 | Mitsubishi Chemical Corporation | Benzamide derivatives |
| US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| CN101500995A (zh) * | 2006-03-17 | 2009-08-05 | 美国政府卫生与公共服务部 | 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物 |
| WO2010104195A1 (en) * | 2009-03-11 | 2010-09-16 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindolin-1-one derivative |
| TW201200505A (en) * | 2010-06-17 | 2012-01-01 | Metabolex Inc | GPR120 receptor agonists and uses thereof |
| WO2014096941A1 (en) * | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| CN105209444A (zh) * | 2013-03-14 | 2015-12-30 | 詹森药业有限公司 | 可用作gpr120的激动剂的苯并稠合杂环衍生物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2735225A (en) | 1956-02-21 | Table ix p petri dish tests with x-phthalimido- | ||
| DE2253251A1 (de) | 1972-10-30 | 1974-05-09 | Thomae Gmbh Dr K | Neue phthalimido-sulfonylharnstoffe |
| EP0145078B1 (en) * | 1983-12-02 | 1988-10-12 | Shell Internationale Researchmaatschappij B.V. | Diphenyl ether herbicides |
| FR2659327A1 (fr) | 1990-03-08 | 1991-09-13 | Centre Nat Rech Scient | Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases. |
| ATE162525T1 (de) | 1991-07-30 | 1998-02-15 | Ciba Geigy Ag | Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren |
| US5350761A (en) * | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| US5599811A (en) * | 1995-02-21 | 1997-02-04 | Warner-Lambert Company | Benzothiazine dioxides as endothelin antagonists |
| EP0891332B1 (en) | 1996-03-29 | 2004-03-17 | Pfizer Inc. | 6-phenylpyridyl-2-amine derivatives |
| US6716836B2 (en) | 2001-03-22 | 2004-04-06 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| NZ577981A (en) * | 2006-12-27 | 2011-12-22 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| AU2008218951B2 (en) * | 2007-02-22 | 2011-11-17 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| US8569378B2 (en) | 2007-07-20 | 2013-10-29 | Toshiyuki Sakai | p27 protein inducer |
| CA2740366A1 (en) | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| CA2801182A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
| EP2731944A1 (en) | 2011-07-15 | 2014-05-21 | Pfizer Inc | Gpr 119 modulators |
| EA035454B1 (ru) | 2011-11-30 | 2020-06-18 | Ф.Хоффманн-Ля Рош Аг | Бициклические производные дигидроизохинолин-1-она |
| RU2015116540A (ru) | 2012-10-11 | 2016-12-10 | Мерк Шарп И Доум Корп. | Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120 |
| KR101942752B1 (ko) * | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| CA2893239A1 (en) | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted triazole and imidazole compounds |
| AU2014237600B2 (en) * | 2013-03-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Bicyclic pyrrole derivatives useful as agonists of GPR120 |
| DK3013796T3 (da) | 2013-06-27 | 2020-03-16 | Lg Chemical Ltd | Biarylderivater som gpr120-agonister |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| BR112016024936A2 (pt) | 2014-05-07 | 2017-08-15 | Bristol Myers Squibb Co | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes |
| CN107074817B (zh) * | 2014-08-29 | 2023-12-15 | Chdi基金会股份有限公司 | 用于成像亨廷顿蛋白的探针 |
| JP6486699B2 (ja) | 2015-01-29 | 2019-03-20 | 国立大学法人金沢大学 | 脱水縮合剤 |
| US10457669B2 (en) * | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| CA3041038A1 (en) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| JP7086942B2 (ja) * | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
-
2017
- 2017-09-11 CA CA3041038A patent/CA3041038A1/en active Pending
- 2017-09-11 WO PCT/US2017/050964 patent/WO2018049328A1/en not_active Ceased
- 2017-09-11 JP JP2019513944A patent/JP7065081B2/ja active Active
- 2017-09-11 US US16/331,928 patent/US10865201B2/en active Active
- 2017-09-11 KR KR1020197010276A patent/KR102539877B1/ko active Active
- 2017-09-11 EP EP17849722.8A patent/EP3509588B1/en active Active
- 2017-09-11 CN CN201780068712.9A patent/CN110121343B/zh active Active
-
2020
- 2020-12-14 US US17/121,165 patent/US11919891B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| EP0548934A1 (en) * | 1991-12-25 | 1993-06-30 | Mitsubishi Chemical Corporation | Benzamide derivatives |
| CN101500995A (zh) * | 2006-03-17 | 2009-08-05 | 美国政府卫生与公共服务部 | 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物 |
| WO2010104195A1 (en) * | 2009-03-11 | 2010-09-16 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindolin-1-one derivative |
| TW201200505A (en) * | 2010-06-17 | 2012-01-01 | Metabolex Inc | GPR120 receptor agonists and uses thereof |
| WO2014096941A1 (en) * | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| CN105209444A (zh) * | 2013-03-14 | 2015-12-30 | 詹森药业有限公司 | 可用作gpr120的激动剂的苯并稠合杂环衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7065081B2 (ja) | 2022-05-11 |
| JP2019533642A (ja) | 2019-11-21 |
| KR20190068535A (ko) | 2019-06-18 |
| US10865201B2 (en) | 2020-12-15 |
| EP3509588C0 (en) | 2023-06-07 |
| US20190218208A1 (en) | 2019-07-18 |
| EP3509588A4 (en) | 2020-04-29 |
| US20210347768A1 (en) | 2021-11-11 |
| EP3509588B1 (en) | 2023-06-07 |
| CN110121343A (zh) | 2019-08-13 |
| EP3509588A1 (en) | 2019-07-17 |
| CA3041038A1 (en) | 2018-03-15 |
| US11919891B2 (en) | 2024-03-05 |
| KR102539877B1 (ko) | 2023-06-05 |
| WO2018049328A1 (en) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110121343B (zh) | 用作gpr120调节剂的双环化合物 | |
| CN110225752B (zh) | 用作gpr120调节器的单环化合物 | |
| CN104470898B (zh) | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 | |
| JP6552061B2 (ja) | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用 | |
| JP2010500372A (ja) | オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物 | |
| JP2019077713A (ja) | ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター | |
| TW201625533A (zh) | Ｋｃｎｑ ２至５通道活化劑 | |
| JP6293266B2 (ja) | 高血圧及び／又は線維症の処置用組成物 | |
| CN107163044A (zh) | 一类具有蛋白酶修饰活性的萘乙二酮化合物及其衍生物 | |
| CN116438174A (zh) | 化合物及其作为mif抑制剂的用途 | |
| JP2009506127A (ja) | 糖尿病の処置に有用なアニリノピラゾール誘導体 | |
| KR20090074179A (ko) | Ｐｐａｒ 조절제로서 유용한 １ｈ인돌２카르복실산 유도체 | |
| TW201708226A (zh) | 吲哚衍生物 | |
| JP5893155B2 (ja) | Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物 | |
| HK40005335A (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005335B (en) | Bicyclic compounds useful as gpr120 modulators | |
| JP2024546944A (ja) | Ｒｘｆｐ１アゴニストとしてのナフタレンおよびキノリン類似体 | |
| CN118715015A (zh) | 选择性phd1抑制剂化合物、组合物和使用方法 | |
| HK40005332B (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005332A (en) | Monocyclic compounds useful as gpr120 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200909 Address after: Massachusetts, USA Applicant after: Overall health Address before: California, USA Applicant before: NUMERATE, Inc. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Massachusetts, USA Patentee after: Valo health Co.,Ltd. Address before: Massachusetts, USA Patentee before: Overall health |
|
| CP01 | Change in the name or title of a patent holder |